Long-term use of tetracycline

Belur Bhagavan, R. E. Wenk, Edward F McCarthy, F. C. Gebhardt, J. A. Lustgarten

Research output: Contribution to journalArticle

Abstract

We recently saw a 21-year-old woman who died of tetracycline-associated fatty liver at 38 weeks of pregnancy and in whom we demonstrated gross and microscopic fluorescence of tetracycline in bone. Tissue extraction and quantitative chemical analysis showed 60 mg of tetracycline per gram of wet bone tissue. Initially, we could elicit no history of tetracycline ingestion from the patient's records and family. Approximately eight months after the death of the patient, a nurse who had taken care of her related that the patient's husband had once told her that the patient had been using tetracycline for acne. However, she had suspended its use during pregnancy. This case points out the possibility that tetracycline may be released from the bone after its incorporation there in the remote past and that it might cause hepatotoxicity in a vulnerable woman at the time of pregnancy. The drug may be stored in the bone in the form of loose complexes with calcium apatite and protein matrix. Such conditions as pregnancy, hyperparathyroidism, acidosis, and osteomalacia might cause bone turnover and the drug molecules may be chelated and released in sufficient quantities to damage an already vulnerable liver.

Original languageEnglish (US)
Pages (from-to)2780
Number of pages1
JournalJournal of the American Medical Association
Volume247
Issue number20
DOIs
StatePublished - 1982

Fingerprint

Tetracycline
Bone and Bones
Pregnancy
Apatites
Osteomalacia
Hyperparathyroidism
Bone Remodeling
Acne Vulgaris
Fatty Liver
Acidosis
Spouses
Pharmaceutical Preparations
Patient Care
Eating
Fluorescence
Nurses
Calcium
Liver
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Long-term use of tetracycline. / Bhagavan, Belur; Wenk, R. E.; McCarthy, Edward F; Gebhardt, F. C.; Lustgarten, J. A.

In: Journal of the American Medical Association, Vol. 247, No. 20, 1982, p. 2780.

Research output: Contribution to journalArticle

Bhagavan, Belur ; Wenk, R. E. ; McCarthy, Edward F ; Gebhardt, F. C. ; Lustgarten, J. A. / Long-term use of tetracycline. In: Journal of the American Medical Association. 1982 ; Vol. 247, No. 20. pp. 2780.
@article{b7f10ea77b2c4bb98b34ad403c0b4bda,
title = "Long-term use of tetracycline",
abstract = "We recently saw a 21-year-old woman who died of tetracycline-associated fatty liver at 38 weeks of pregnancy and in whom we demonstrated gross and microscopic fluorescence of tetracycline in bone. Tissue extraction and quantitative chemical analysis showed 60 mg of tetracycline per gram of wet bone tissue. Initially, we could elicit no history of tetracycline ingestion from the patient's records and family. Approximately eight months after the death of the patient, a nurse who had taken care of her related that the patient's husband had once told her that the patient had been using tetracycline for acne. However, she had suspended its use during pregnancy. This case points out the possibility that tetracycline may be released from the bone after its incorporation there in the remote past and that it might cause hepatotoxicity in a vulnerable woman at the time of pregnancy. The drug may be stored in the bone in the form of loose complexes with calcium apatite and protein matrix. Such conditions as pregnancy, hyperparathyroidism, acidosis, and osteomalacia might cause bone turnover and the drug molecules may be chelated and released in sufficient quantities to damage an already vulnerable liver.",
author = "Belur Bhagavan and Wenk, {R. E.} and McCarthy, {Edward F} and Gebhardt, {F. C.} and Lustgarten, {J. A.}",
year = "1982",
doi = "10.1001/jama.247.20.2780",
language = "English (US)",
volume = "247",
pages = "2780",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "20",

}

TY - JOUR

T1 - Long-term use of tetracycline

AU - Bhagavan, Belur

AU - Wenk, R. E.

AU - McCarthy, Edward F

AU - Gebhardt, F. C.

AU - Lustgarten, J. A.

PY - 1982

Y1 - 1982

N2 - We recently saw a 21-year-old woman who died of tetracycline-associated fatty liver at 38 weeks of pregnancy and in whom we demonstrated gross and microscopic fluorescence of tetracycline in bone. Tissue extraction and quantitative chemical analysis showed 60 mg of tetracycline per gram of wet bone tissue. Initially, we could elicit no history of tetracycline ingestion from the patient's records and family. Approximately eight months after the death of the patient, a nurse who had taken care of her related that the patient's husband had once told her that the patient had been using tetracycline for acne. However, she had suspended its use during pregnancy. This case points out the possibility that tetracycline may be released from the bone after its incorporation there in the remote past and that it might cause hepatotoxicity in a vulnerable woman at the time of pregnancy. The drug may be stored in the bone in the form of loose complexes with calcium apatite and protein matrix. Such conditions as pregnancy, hyperparathyroidism, acidosis, and osteomalacia might cause bone turnover and the drug molecules may be chelated and released in sufficient quantities to damage an already vulnerable liver.

AB - We recently saw a 21-year-old woman who died of tetracycline-associated fatty liver at 38 weeks of pregnancy and in whom we demonstrated gross and microscopic fluorescence of tetracycline in bone. Tissue extraction and quantitative chemical analysis showed 60 mg of tetracycline per gram of wet bone tissue. Initially, we could elicit no history of tetracycline ingestion from the patient's records and family. Approximately eight months after the death of the patient, a nurse who had taken care of her related that the patient's husband had once told her that the patient had been using tetracycline for acne. However, she had suspended its use during pregnancy. This case points out the possibility that tetracycline may be released from the bone after its incorporation there in the remote past and that it might cause hepatotoxicity in a vulnerable woman at the time of pregnancy. The drug may be stored in the bone in the form of loose complexes with calcium apatite and protein matrix. Such conditions as pregnancy, hyperparathyroidism, acidosis, and osteomalacia might cause bone turnover and the drug molecules may be chelated and released in sufficient quantities to damage an already vulnerable liver.

UR - http://www.scopus.com/inward/record.url?scp=0020472785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020472785&partnerID=8YFLogxK

U2 - 10.1001/jama.247.20.2780

DO - 10.1001/jama.247.20.2780

M3 - Article

C2 - 7077774

AN - SCOPUS:0020472785

VL - 247

SP - 2780

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 20

ER -